What type of anti-cancer drug is Telisotuzumab?

Telisotuzumab (Telisotuzumab Vedotin, referred to as Teliso-V) is an antibody - drug conjugate (ADC), which targets the c-MET protein. This drug couples some potent cytotoxic chemotherapy drugs (such as monomethyl auristatin E, MMAE) to monoclonal antibodies that specifically recognize c-MET through chemical linkage, allowing it to target tumor cells expressing the target. c-MET is a tyrosine kinase receptor overexpressed in a variety of solid tumors (such as non-small cell lung cancer), making it an important breakthrough for the new generation of targeted therapy.

The mechanism of action of Teliso-V is: its antibody part specifically recognizes and binds to the c-MET receptor on the surface of tumor cells. After the drug enters the tumor cells, it releases MMAE within the cells, thereby blocking the assembly of microtubules and triggering cell apoptosis. This design allows Teliso-V to improve treatment selectivity while minimizing toxic damage to normal tissues. Therefore, compared with traditional chemotherapy, Teliso-V is more targeted and has advantages in efficacy, and is especially suitable for patients with high c-MET expression but lack of other targets.

CurrentlyTelisotuzumab Vedotinis mainly in the III clinical research stage for advanced non-small cell lung cancer (NSCLC), especially in patients with EGFR wild type and c-MET high expression, showing good prospects. In previous studies, Teliso-VMonotherapy has shown a certain tumor response rate and tolerability, and is expected to become an important option for patients who have failed previous treatments. It is also trying to be combined with other targeted drugs (such as EGFR inhibitors) or immunotherapy to enhance therapeutic synergy.

Overall, Telisotuzumab vedotin is a new ADC drug that is expected to be used to treat a variety of solid tumors, especially in the field of non-small cell lung cancer. Although it has not yet been officially approved for marketing by the FDA or NMPA, its clinical research data has attracted widespread attention. If the key phase III trials can be successfully completed in the future and passed through the drug approval process, Teliso-V is expected to become another important addition to the field of precision tumor treatment.

Reference materials:https://www.drugs.com/